Abliva AB (EM) (NEVPF)

Abliva AB (publ) develops medicines for the treatment of mitochondrial diseases. The company maintains a portfolio that includes projects at various stages, from early discovery to clinical phase. Its lead candidate, KL1333, targets fatigue and muscle weakness in adult patients with genetically conf... Abliva AB (publ) develops medicines for the treatment of mitochondrial diseases. The company maintains a portfolio that includes projects at various stages, from early discovery to clinical phase. Its lead candidate, KL1333, targets fatigue and muscle weakness in adult patients with genetically confirmed primary mitochondrial disease. Another product, NV354, uses prodrug technology to deliver succinate to cells for conditions such as Leigh syndrome, while NV556 is evaluated as a cyclophilin inhibitor for liver fibrosis and hepatocellular carcinoma. The company conducts research and development focused on the regulation and stabilization of cellular energy production and collaborates with patient organizations as part of its development approach. The company was founded in 2000 and is based in Lund, Sweden. Show more